New study targets ovarian cancer in black women: could genes affect treatment?

NCT ID NCT06412120

Recruiting now Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take niraparib pills to help keep cancer from coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Ahmadu Bello University Teaching Hospital (ABUTH)
RECRUITING

Zaria, Kaduna State, Nigeria
Broward Health
RECRUITING

Fort Lauderdale, Florida, 33316, United States
University of Florida Jacksonville
RECRUITING

Jacksonville, Florida, 32209, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.